Fintel reports that on September 26, 2023, Stifel reiterated coverage of Glaukos (NYSE:GKOS) with a Buy recommendation.
Analyst Price Forecast Suggests 13.87% Upside
As of August 31, 2023, the average one-year price target for Glaukos is 85.91. The forecasts range from a low of 68.68 to a high of $94.50. The average price target represents an increase of 13.87% from its latest reported closing price of 75.44.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Glaukos is 315MM, an increase of 6.01%. The projected annual non-GAAP EPS is -1.75.
What is the Fund Sentiment?
There are 502 funds or institutions reporting positions in Glaukos. This is an increase of 30 owner(s) or 6.36% in the last quarter. Average portfolio weight of all funds dedicated to GKOS is 0.22%, an increase of 27.24%. Total shares owned by institutions increased in the last three months by 4.00% to 58,642K shares. 
The put/call ratio of GKOS is 0.44, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 3,954K shares representing 8.13% ownership of the company. In it's prior filing, the firm reported owning 4,685K shares, representing a decrease of 18.49%. The firm increased its portfolio allocation in GKOS by 14.47% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 3,378K shares representing 6.95% ownership of the company. In it's prior filing, the firm reported owning 3,480K shares, representing a decrease of 3.01%. The firm increased its portfolio allocation in GKOS by 33.63% over the last quarter.
Brown Capital Management holds 2,637K shares representing 5.42% ownership of the company. In it's prior filing, the firm reported owning 2,905K shares, representing a decrease of 10.15%. The firm increased its portfolio allocation in GKOS by 22.48% over the last quarter.
Artisan Partners Limited Partnership holds 1,858K shares representing 3.82% ownership of the company. In it's prior filing, the firm reported owning 1,875K shares, representing a decrease of 0.90%. The firm increased its portfolio allocation in GKOS by 37.73% over the last quarter.
Fred Alger Management holds 1,631K shares representing 3.35% ownership of the company. In it's prior filing, the firm reported owning 1,521K shares, representing an increase of 6.73%. The firm increased its portfolio allocation in GKOS by 54.92% over the last quarter.
Glaukos Background Information
(This description is provided by the company.)
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
